Efficacy and safety of immunotherapy for allergic rhinitis in the induction phase

• DOI: 10.22533/at.ed.1593432306069

• Palavras-chave: efficacy, induction, subcutaneous immunotherapy, allergic rhinitis, safety.

• Keywords: efficacy, induction, subcutaneous immunotherapy, allergic rhinitis, safety.

• Abstract:

  Introduction. Allergen immunotherapy is an effective treatment for allergic rhinitis.Aim: to evaluate the efficacy and safety of subcutaneous immunotherapy during the induction phase according to the 2019 Mexican Immunotherapy Guide in patients with allergic rhinitis.Material and methods: analytical, prospective, quasi-experimental, longitudinal study in patients from 2 to 65 years of age with allergic rhinitis. Total Nasal Symptom Score and Portnoy were performed at the beginning and every two months, the data was analyzed with the IBM SPSS Statistics version 28 program. Summary and dispersion measures were used, comparing percentages by X2 and comparing means by variance ot Student test, considering a value of p <0.05 as statistically significant.Results: 44 patients (22 women) were included, mean age 27.9 years. Mean symptom score before starting immunotherapy: 7.15, 4.04 at 2 months, 3.20 at 4 months and 2.77 at 6 months. Adverse effects occurred in 7.9% of the applications.Conclusions: The modifications stipulated for the induction phase in the 2019 Mexican Immunotherapy Guide are safe and effective in allergic rhinitis.